Impact of the Rapid Expansion of Pre-exposure Prophylaxis (PrEP) on HIV Incidence, in a Setting With High HIV Testing and ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2016-2019

ABSTRACT

A new NSW Ministry of Health HIV Strategy released on 1 December 2015 aims for the virtual elimination of HIV transmission in NSW by 2020. Critical to the new strategy's success is the population-based, targeted roll-out of HIV PrEP. PrEP involves taking one pill daily of co-formulated tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC). This large-scale study aims for the rapid roll-out of TDF/FTC to individuals at high risk of HIV, who will comprise mostly gay and bisexual men (GBM) but will also include small numbers of heterosexuals, injecting drug users, and transgender men and women. The drug will be used according to existing NSW Ministry of Health Guidelines. By rapidly rolling out this new intervention over a 12 month period, and following participants for two years on treatments, a reduction of about 50% in new HIV diagnoses in NSW is expected. The study aims to assess the incidence of HIV among PrEP study participants and measure the population-level impact of the rapid roll-out of PrEP on HIV diagnoses among GBM in NSW over a two-year period. It will also evaluate the rate of PrEP uptake among high risk GBM in NSW, assess the incidence of STI (gonorrhoea, chlamydia and infectious syphilis) among people prescribed PrEP and measure the effect of the rapid roll-out of PrEP on the overall number of notifications of gonorrhoea, chlamydia and infectious syphilis in NSW, describe patterns of PrEP use and medication adherence, and monitor behavioural risk practices among PrEP users. The main population group will be more than 3700 gay men at high risk of HIV infection. All procedures of this study are guided by the NSW Guidelines on PrEP. Protocol Co-Chairs Professor David Cooper, Professor Andrew Grulich. Project Manager: Barbara Yeung More... »

URL

https://clinicaltrials.gov/show/NCT02870790

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "A new NSW Ministry of Health HIV Strategy released on 1 December 2015 aims for the virtual elimination of HIV transmission in NSW by 2020. Critical to the new strategy's success is the population-based, targeted roll-out of HIV PrEP. PrEP involves taking one pill daily of co-formulated tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC). This large-scale study aims for the rapid roll-out of TDF/FTC to individuals at high risk of HIV, who will comprise mostly gay and bisexual men (GBM) but will also include small numbers of heterosexuals, injecting drug users, and transgender men and women. The drug will be used according to existing NSW Ministry of Health Guidelines. By rapidly rolling out this new intervention over a 12 month period, and following participants for two years on treatments, a reduction of about 50% in new HIV diagnoses in NSW is expected. The study aims to assess the incidence of HIV among PrEP study participants and measure the population-level impact of the rapid roll-out of PrEP on HIV diagnoses among GBM in NSW over a two-year period. It will also evaluate the rate of PrEP uptake among high risk GBM in NSW, assess the incidence of STI (gonorrhoea, chlamydia and infectious syphilis) among people prescribed PrEP and measure the effect of the rapid roll-out of PrEP on the overall number of notifications of gonorrhoea, chlamydia and infectious syphilis in NSW, describe patterns of PrEP use and medication adherence, and monitor behavioural risk practices among PrEP users. The main population group will be more than 3700 gay men at high risk of HIV infection. All procedures of this study are guided by the NSW Guidelines on PrEP. Protocol Co-Chairs Professor David Cooper, Professor Andrew Grulich. Project Manager: Barbara Yeung", 
    "endDate": "2019-06-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02870790", 
    "keywords": [
      "pre-exposure prophylaxis", 
      "PrEP", 
      "HIV incidence", 
      "HIV testing", 
      "antiretroviral treatment", 
      "Achieve", 
      "HIV transmission", 
      "Implementation Project", 
      "Ministry of Health", 
      "elimination", 
      "NSW", 
      "success", 
      "roll-out", 
      "pill", 
      "emtricitabine", 
      "FTC", 
      "large-scale study", 
      "tenofovir", 
      "individual", 
      "high risk", 
      "HIV", 
      "gay and bisexual men", 
      "small number", 
      "Heterosexuality", 
      "injecting drug users", 
      "transgender", 
      "woman", 
      "drug", 
      "rolling", 
      "intervention", 
      "period", 
      "reduction", 
      "HIV diagnosise", 
      "incidence", 
      "study participant", 
      "Weight and Measure", 
      "population-level impact", 
      "diagnosise", 
      "uptake", 
      "STIs", 
      "gonorrhea", 
      "Chlamydia", 
      "syphilis", 
      "overall number", 
      "notification", 
      "pattern", 
      "medication adherence", 
      "behavioral risk", 
      "Population Group", 
      "gay men", 
      "HIV infection", 
      "method", 
      "guideline", 
      "co-chairs", 
      "project manager", 
      "Barbara"
    ], 
    "name": "Impact of the Rapid Expansion of Pre-exposure Prophylaxis (PrEP) on HIV Incidence, in a Setting With High HIV Testing and Antiretroviral Treatment Coverage, to Achieve the Virtual Elimination of HIV Transmission by 2020: a NSW HIV Strategy Implementation Project", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02870790"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00022.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.416790.d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.452312.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412703.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.1005.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413249.9", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.437825.f", 
        "type": "Organization"
      }
    ], 
    "startDate": "2016-03-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/s12889-017-5018-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100800971", 
          "https://doi.org/10.1186/s12889-017-5018-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12889-017-5018-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100800971", 
          "https://doi.org/10.1186/s12889-017-5018-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02870790"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02870790'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02870790'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02870790'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02870790'


 

This table displays all metadata directly associated to this object as RDF triples.

92 TRIPLES      16 PREDICATES      78 URIs      65 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02870790 schema:about anzsrc-for:3053
2 anzsrc-for:3177
3 schema:description A new NSW Ministry of Health HIV Strategy released on 1 December 2015 aims for the virtual elimination of HIV transmission in NSW by 2020. Critical to the new strategy's success is the population-based, targeted roll-out of HIV PrEP. PrEP involves taking one pill daily of co-formulated tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC). This large-scale study aims for the rapid roll-out of TDF/FTC to individuals at high risk of HIV, who will comprise mostly gay and bisexual men (GBM) but will also include small numbers of heterosexuals, injecting drug users, and transgender men and women. The drug will be used according to existing NSW Ministry of Health Guidelines. By rapidly rolling out this new intervention over a 12 month period, and following participants for two years on treatments, a reduction of about 50% in new HIV diagnoses in NSW is expected. The study aims to assess the incidence of HIV among PrEP study participants and measure the population-level impact of the rapid roll-out of PrEP on HIV diagnoses among GBM in NSW over a two-year period. It will also evaluate the rate of PrEP uptake among high risk GBM in NSW, assess the incidence of STI (gonorrhoea, chlamydia and infectious syphilis) among people prescribed PrEP and measure the effect of the rapid roll-out of PrEP on the overall number of notifications of gonorrhoea, chlamydia and infectious syphilis in NSW, describe patterns of PrEP use and medication adherence, and monitor behavioural risk practices among PrEP users. The main population group will be more than 3700 gay men at high risk of HIV infection. All procedures of this study are guided by the NSW Guidelines on PrEP. Protocol Co-Chairs Professor David Cooper, Professor Andrew Grulich. Project Manager: Barbara Yeung
4 schema:endDate 2019-06-01T00:00:00Z
5 schema:keywords Achieve
6 Barbara
7 Chlamydia
8 FTC
9 HIV
10 HIV diagnosise
11 HIV incidence
12 HIV infection
13 HIV testing
14 HIV transmission
15 Heterosexuality
16 Implementation Project
17 Ministry of Health
18 NSW
19 Population Group
20 PrEP
21 STIs
22 Weight and Measure
23 antiretroviral treatment
24 behavioral risk
25 co-chairs
26 diagnosise
27 drug
28 elimination
29 emtricitabine
30 gay and bisexual men
31 gay men
32 gonorrhea
33 guideline
34 high risk
35 incidence
36 individual
37 injecting drug users
38 intervention
39 large-scale study
40 medication adherence
41 method
42 notification
43 overall number
44 pattern
45 period
46 pill
47 population-level impact
48 pre-exposure prophylaxis
49 project manager
50 reduction
51 roll-out
52 rolling
53 small number
54 study participant
55 success
56 syphilis
57 tenofovir
58 transgender
59 uptake
60 woman
61 schema:name Impact of the Rapid Expansion of Pre-exposure Prophylaxis (PrEP) on HIV Incidence, in a Setting With High HIV Testing and Antiretroviral Treatment Coverage, to Achieve the Virtual Elimination of HIV Transmission by 2020: a NSW HIV Strategy Implementation Project
62 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02870790
63 schema:sdDatePublished 2019-03-07T15:26
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N9e1f1788665f4d048c5317a2d1c0ad7d
66 schema:sponsor https://www.grid.ac/institutes/grid.1005.4
67 https://www.grid.ac/institutes/grid.412703.3
68 https://www.grid.ac/institutes/grid.413249.9
69 https://www.grid.ac/institutes/grid.416790.d
70 https://www.grid.ac/institutes/grid.437825.f
71 https://www.grid.ac/institutes/grid.452312.3
72 schema:startDate 2016-03-01T00:00:00Z
73 schema:subjectOf sg:pub.10.1186/s12889-017-5018-9
74 schema:url https://clinicaltrials.gov/show/NCT02870790
75 sgo:license sg:explorer/license/
76 sgo:sdDataset clinical_trials
77 rdf:type schema:MedicalStudy
78 N9e1f1788665f4d048c5317a2d1c0ad7d schema:name Springer Nature - SN SciGraph project
79 rdf:type schema:Organization
80 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
81 rdf:type schema:DefinedTerm
82 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
83 rdf:type schema:DefinedTerm
84 sg:pub.10.1186/s12889-017-5018-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100800971
85 https://doi.org/10.1186/s12889-017-5018-9
86 rdf:type schema:CreativeWork
87 https://www.grid.ac/institutes/grid.1005.4 schema:Organization
88 https://www.grid.ac/institutes/grid.412703.3 schema:Organization
89 https://www.grid.ac/institutes/grid.413249.9 schema:Organization
90 https://www.grid.ac/institutes/grid.416790.d schema:Organization
91 https://www.grid.ac/institutes/grid.437825.f schema:Organization
92 https://www.grid.ac/institutes/grid.452312.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...